P3.18 A Phase 1 multiple ascending dose study to assess the pharmacodynamic effects of ACE-031, an inhibitor of negative muscle regulators, in healthy volunteers von Borgstein, N.G, Barger, R, Yang, Y, Wilson, D.M, Haltom, E, Attie, K.M, Sherman, M.L

Volltext

M.P.1.03 Preliminary results from single subcutaneous administration of ACE-031, a form of the soluble activin type IIB receptor, in healthy postmenopausal volunteers von Borgstein, N.G, Condon, C.H, Yang, Y, Wilson, D.M, Haltom, E, Lachey, J.L, Seehra, J, Sherman, M.L

Volltext

465 DISCUSSION A Phase 1 dose escalating study of ACE-041, a novel inhibitor of ALK-1 mediated angiogenesis, in patients with advanced solid tumors von Sharma, S, Bendell, J.C, Hurwitz, H, Condon, C.H, Thornell, B.J, Slatcher, P.L, Borgstein, N.G, Sherman, M.L, Gordon, M.S

Volltext

No effect of amisulpride on lithium pharmacokinetics von Canal, M., Chaufour, S., Zieleniuk, I., Borgstein, N.G., Pinquier, J.L.

Volltext

Repeated administrations of amisulpride (A) do not modify lithium carbonate (L) pharmacokinetics in healthy volunteers von Chaufour, S., Borgstein, N.G., Van den Eynde, W., Bernard, F., Canal, M., Zieleniuk, I., Pinquier, J.L.

Volltext